New strategies for targeted payload delivery using small engineered scaffold proteins
|Coordinator||Kungliga Tekniska Högskolan - Skolan för kemi, bioteknologi och hälsa|
|Funding from Vinnova||SEK 9 775 000|
|Project duration||June 2019 - May 2022|
|Venture||Protein research and process development within the area of Biologics|
|Call||Protein research and process development for biologics - larger projects|
Purpose and goal
The aim of the project is to explore innovative principles that could form the basis in development of next-generation biological drugs against cancer.
Expected results and effects
The project is expected to generate important knowledge on the impact of molecular design of protein-based drugs on their pharmacokinetic and tumour-suppressing properties. The cooperation between academia and industry would result in more efficient development of next-generation drugs by the company Affibody AB, increasing the the competitiveness of Swedish life science industry. The project might have long-term impact on treatment options as well as promoting development of affinity proteins as biopharmaceuticals.
Planned approach and implementation
We will investigate payload therapies against cancer in three subprojects: 1) targeted delivery of cytotoxic drugs and toxins, 2) pretargeting technologies for radiotherapy and 3) prodrug biologics for increased specificity. The studies will be organized in work packages: WP1) molecular design and protein engineering of targeting conjugates, WP2) production, purification and in vitro characterization of targeting conjugates, WP3) pharmacokinetics and preclinical therapy and WP4) industrial implementation and identification of potentially new IP.